None of the 29 investors followed here reported a position in PMVP in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a PMVP trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 26, 2025 | Mack David HenryChief Executive Officer | Conversion of Exercise of derivative security at price 1.37 per share. | 220.6K | $302.28K |
| Oct 22, 2025 | Orbimed Advisors, L.L.C.Beneficial Owner of more than 10% of a Class of Security | Sale at price 1.52 per share. | 1.00M | $1.52M |
| Sep 9, 2025 | Orbimed Advisors, L.L.C.Beneficial Owner of more than 10% of a Class of Security | Sale at price 1.27 per share. | 500K | $635.00K |
| Jun 30, 2025 | Mack David HenryChief Executive Officer | Sale at price 1.06 per share. | 58.4K | $62.18K |
| Jun 30, 2025 | Ticktin RobertChief Operating Officer | Sale at price 1.06 per share. | 23.2K | $24.65K |
| Jun 30, 2025 | Jalota DeepikaOfficer | Sale at price 1.06 per share. | 33.1K | $35.20K |
| Jun 30, 2025 | Carulli MichaelChief Financial Officer | Sale at price 1.06 per share. | 28.2K | $30.08K |
| Jan 2, 2025 | Mack David HenryChief Executive Officer | Conversion of Exercise of derivative security at price 0.53 per share. | 109.5K | $58.01K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -13.6 | 57.4 | -27.1 | 12.1 | -13.7 | 11.7 | -17.2 | 9.0 | 38.0 | -19.2 | +8.0% | ||
| 2025 | -6.0 | -3.5 | -20.4 | -9.2 | -11.3 | 20.7 | 34.0 | -1.4 | 0.0 | 0.7 | -6.4 | -5.3 | −17.2% |
| 2024 | -43.2 | 5.1 | -8.1 | 5.9 | 1.1 | -11.0 | 2.5 | -5.4 | -5.1 | 9.4 | -0.6 | -6.8 | −51.3% |
| 2023 | -5.7 | -12.1 | -33.8 | -3.4 | 16.1 | 17.0 | 4.5 | 10.4 | -15.0 | -75.4 | 51.7 | 35.4 | −64.4% |
| 2022 | -30.5 | -1.4 | 31.4 | -30.4 | -18.8 | 21.2 | 4.9 | -6.9 | -14.5 | 3.4 | -18.9 | -12.8 | −62.3% |
| 2021 | -44.5 | 10.2 | -12.6 | 2.6 | 2.0 | -0.7 | -0.4 | -10.8 | -1.8 | -20.7 | -7.9 | 6.2 | −62.4% |
| 2020 | -1.3 | 0.5 | 74.5 | +73.3% |
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Princeton, New Jersey.
Buy / hold / sell counts